title: Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy.
abstract: A soluble form of CD8 antigen (sCD8) has been shown to be released by activated CD8 + lymphocytes. Measurements of sCD8 may serve as an index of suppressor/cytotoxic cell activity. To assess the clinical significance of this observation in response to malignancy, we have investigated the sCD8 concentrations in 38 patients with hairy cell leukemia (HCL) not yet treated with any systemic therapy. The median plasma sCD8 level of the 20 nonsplenectomized patients was 1,025 U/ml and was significantly higher than that in the 18 patients who had previous splenectomy (median = 200 U/ml, p less than 0.0001), or in 14 normal controls (median = 350 U/ml, p less than 0.0001). Compared to controls, splenectomized patients had also significantly lower levels of sCD8 (p less than 0.01). The median concentration of soluble interleukin-2 receptor (sIL2R) in nonsplenectomized patients was 14,500 U/ml and was in the same range as in splenectomized patients (15,000 U/ml). There was no overlap in sIL2-R levels between controls (median = 300 U/ml) and patients. Investigation of serial plasma samples in 7 patients who received deoxycoformycin (DCF) and 11 patients treated with interferon alpha (IFN-alpha) showed a normalization of sCD8 levels and a decrease of sIL2R concentrations in those patients who showed hematological improvement. Normalization of sIL2R was, however, only observed in patients with complete remission. Our observation indicates that splenectomy might cause a reduction of the activation of suppressor/cytotoxic cells in patients with HCL. Treatment with either DCF or IFN-alpha also modulates the sCD8 levels to normal range. Measurements of sCD8 and sIL2-R might give more insight into the pathogenesis of HCL and serve as parameters for monitoring different phases of the disease and response to therapy.
authors.affiliation: Department of Internal Medicine and Poliklinik, University of Heidelberg, F.R.G.
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.forename: M
authors.initials: M
authors.lastname: Grossmann
authors.forename: W
authors.initials: W
authors.lastname: Knauf
authors.forename: H
authors.initials: H
authors.lastname: Martin
authors.forename: L
authors.initials: L
authors.lastname: Trümper
authors.forename: T
authors.initials: T
authors.lastname: Zwingers
authors.forename: R
authors.initials: R
authors.lastname: Sonnen
authors.forename: H
authors.initials: H
authors.lastname: Pralle
authors.forename: W
authors.initials: W
authors.lastname: Hunstein
mesh_terms: D000941:Antigens / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D016827:CD8 Antigens; D003070:Coformycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007943:Leukemia, Hairy Cell / Q000276:immunology* / Q000628:therapy; D015649:Pentostatin; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D013156:Splenectomy
chemical_list: D000941:Antigens; D000945:Antigens, Differentiation, T-Lymphocyte; D016827:CD8 Antigens; D007370:Interferon Type I; D015375:Receptors, Interleukin-2; D003070:Coformycin; D015649:Pentostatin